GlassScriptPhysician profile
Del Ray Gardner
NPI 1336157585
$7,744.08
in general payments reported to CMS, 2019-2025
40 companies · $1,065 in 2025
The $1,065 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,322 · 2020: $569 · 2021: $1,348 · 2022: $892 · 2023: $1,848 · 2024: $699 · 2025: $1,065.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,612.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,612.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,184.78 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,145.35 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $934.93 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Allergan, INC. | $423.25 | 2019-2021 | |
| Abbott Laboratories | $373.44 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $341.37 | 2019-2023 | Jardiance |
| Pfizer INC. | $323.24 | 2020-2025 | |
| Amgen INC. | $298.45 | 2019-2024 | Repatha, Otezla |
| Astellas Pharma US INC | $278.12 | 2023-2024 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $250.09 | 2023-2025 | |
| Biohaven Pharmaceuticals, INC. | $230.27 | 2021 | |
| Sanofi-Aventis U.S. LLC | $225.90 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $207.87 | 2019-2023 | Steglatro, Januvia, Belsomra |
| Glaxosmithkline, LLC. | $162.19 | 2020-2023 | Shingrix, Arexvy, Trelegy Ellipta |
| Lilly USA, LLC | $147.50 | 2021-2023 | Jardiance, Mounjaro |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Del Gardner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.